130 related articles for article (PubMed ID: 22192742)
1. [In cauda venenum or the importance of TET(2)].
Mercher T; Quivoron C; Couronné L; Vainchenker W; Bastard C; Bernard OA
Med Sci (Paris); 2011 Dec; 27(12):1064-6. PubMed ID: 22192742
[No Abstract] [Full Text] [Related]
2. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Schaub FX; Lehmann T; Looser R; Hao-Shen H; Tichelli A; Skoda RC
Blood; 2011 Feb; 117(6):2075-6. PubMed ID: 21310937
[No Abstract] [Full Text] [Related]
3. TET2: epigenetic safeguard for HSC.
Ko M; Rao A
Blood; 2011 Oct; 118(17):4501-3. PubMed ID: 22033942
[No Abstract] [Full Text] [Related]
4. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
[TBL] [Abstract][Full Text] [Related]
5. [Aberrant cytosine hydroxymethylation in hematologic malignancies].
Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2013 May; 54(5):423-30. PubMed ID: 23727679
[No Abstract] [Full Text] [Related]
6. From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.
Möröy T; Vassen L; Wilkes B; Khandanpour C
Blood; 2015 Dec; 126(24):2561-9. PubMed ID: 26447191
[TBL] [Abstract][Full Text] [Related]
7. BCL-6 in diffuse large-cell lymphomas.
Dalla-Favera R; Ye BH; Cattoretti G; Lo Coco F; Chang CC; Zhang J; Migliazza A; Cechova K; Niu H; Chaganti S; Chen W; Louie DC; Offit K; Chaganti RS
Important Adv Oncol; 1996; ():139-48. PubMed ID: 8791133
[No Abstract] [Full Text] [Related]
8. [TET2 dysregulation in hematologic malignancies].
Sakata-Yanagimoto M
Rinsho Ketsueki; 2014 Oct; 55(10):1893-902. PubMed ID: 25297753
[No Abstract] [Full Text] [Related]
9. Gfi-1: another piece in the HSC puzzle.
Cellot S; Sauvageau G
Trends Immunol; 2005 Feb; 26(2):68-71. PubMed ID: 15668120
[No Abstract] [Full Text] [Related]
10. The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells.
Zhao Z; Chen S; Zhu X; Pan F; Li R; Zhou Y; Yuan W; Ni H; Yang FC; Xu M
Leukemia; 2016 Aug; 30(8):1784-1788. PubMed ID: 27003514
[No Abstract] [Full Text] [Related]
11. Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease.
Fuster JJ; Walsh K
Circ Res; 2018 Feb; 122(3):523-532. PubMed ID: 29420212
[TBL] [Abstract][Full Text] [Related]
12. Controlling apoptosis: implications for carcinogenesis?
Clarke AR
Symp Soc Exp Biol; 2000; 52():265-75. PubMed ID: 12090014
[No Abstract] [Full Text] [Related]
13. TET2 in Normal and Malignant Hematopoiesis.
Bowman RL; Levine RL
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28242787
[TBL] [Abstract][Full Text] [Related]
14. MYC levels govern hematopoietic tumor type and latency in transgenic mice.
Smith DP; Bath ML; Metcalf D; Harris AW; Cory S
Blood; 2006 Jul; 108(2):653-61. PubMed ID: 16537801
[TBL] [Abstract][Full Text] [Related]
15. Acute loss of TET function results in aggressive myeloid cancer in mice.
An J; González-Avalos E; Chawla A; Jeong M; López-Moyado IF; Li W; Goodell MA; Chavez L; Ko M; Rao A
Nat Commun; 2015 Nov; 6():10071. PubMed ID: 26607761
[TBL] [Abstract][Full Text] [Related]
16. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
Li R; Xu MJ; Yang FC; Zhou Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
[TBL] [Abstract][Full Text] [Related]
17. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
[TBL] [Abstract][Full Text] [Related]
18. TET2, a tumor suppressor in hematological disorders.
Mercher T; Quivoron C; Couronné L; Bastard C; Vainchenker W; Bernard OA
Biochim Biophys Acta; 2012 Apr; 1825(2):173-7. PubMed ID: 22240200
[TBL] [Abstract][Full Text] [Related]
19. TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2
Li R; Zhou Y; Cao Z; Liu L; Wang J; Chen Z; Xing W; Chen S; Bai J; Yuan W; Cheng T; Xu M; Yang FC; Zhao Z
Stem Cell Reports; 2018 Jan; 10(1):166-179. PubMed ID: 29290626
[TBL] [Abstract][Full Text] [Related]
20. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
